• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease

    2020-12-18 06:07:36LauraHammerStaciaFurtadoEdithMathiowitzDominickAuci

    Laura Hammer, Stacia Furtado, Edith Mathiowitz, Dominick L Auci

    Abstract

    Key Words: Transforming growth factor beta; All trans retinoic acid; Ulcerative colitis;Crohn’s disease; Inflammatory bowel disease; Regulatory T cells

    INTRODUCTION

    TreXTAM?is a proprietary micro-encapsulated drug product in development as an oral treatment for inflammatory bowel disease (IBD).It is the combination of the key regulatory cytokine transforming growth factor beta (TGFβ) encapsulated in into polylactic acid (PLA) particles; along with a signaling form of vitamin A, all trans retinoic acid (ATRA), encapsulated in poly D,L-lactide-co-glycolide (PLGA) particles[1].Simultaneous ATRA and TGFβ signals synergize in promoting the differentiation and stabilization of regulatory T cells[2].This is a completely novel strategy for the treatment of IBD, as no similar products exist.However, unlike ATRA, TGFβ is a protein macromolecule that must be protected against hydrolysis in the stomach to be effectiveviathe oral route[3].

    Encapsulation remains one of the most promising methods to protect drug substances and to achieve local, sustained release.Efforts have generally focused on siRNA[4], small molecules[5], peptides[6]and cytokines[7]and involve polymer encapsulation accomplishedviacombinations of phase separation or precipitation,emulsion/solvent evaporation[8-15]and/or spraying methods[16-20].However, loss of bioactivity during manufacturing, poorly controlled release rates, and difficulties with large-scale production of accurately sized particles are some of the formidable challenges preventing commercialization.

    To address these challenges, we pioneered the development of phase inversion nano-encapsulation (PIN?) technology that utilizes a non-mechanical approach to preserve the structural integrity of macromolecules during the drug product manufacturing process.PIN encapsulated cytokines have demonstrated stability,bioactivity and efficacy in various preclinical models[21-26].Particles with an average diameter of 0.1-5 microns[6], are ideally suited to oral delivery as particles smaller than 5 microns in diameter readily traverse the gastrointestinal barrier[27-29].Indeed, we had previously shown that orally administered insulin encapsulated in PIN particles resulted in localization of drug product to the gut, and efficient uptake at the intestinal border[6,7].

    More recently we applied PIN technology to the development of TreXTAM and showed that oral administration effectively ameliorated disease in two different rodent IBD models[1].Broadly, treatment of mice with established disease using the optimized dose/frequency regimen, achieved a dramatic 2 to 9-fold reduction in multiple markers of disease compared to control groups within 2 wk, in some cases approaching normal values.Importantly, treatment enhanced long-term survival over eight weeks with no detectable toxicity.Activity was associated with enhanced Foxp3 expression in the colonic lamina propria CD4+ CD25+ T-cells, and required both TGFβ and ATRA for maximal efficacy.We have recently reviewed potential cellular and molecular mechanisms driving synergy, including cross-talk between ATRA and TGFβ signal transduction pathways[2].

    During TreXTAM development, we studied TGFβ pharmacokinetics after oral administration of TreXTAM, or after the encapsulated cytokine (TPX6001) was given alone, without ATRA.We made the surprising discovery that oral administration of TreXTAM dramatically reduced TGFβ levels in colon and in blood, to below baseline levels.When encapsulated TGFβ (TPX6001) was given alone, three times a week for 25 d, we likewise observed serum TGFβ decreases below baseline (untreated) levels.Oral treatment with TPX6001 alone transiently ameliorated weight loss in the murine adoptive cell transfer (ACT) model of IBD.These observations suggest a negative feedback mechanism in the gut whereby local delivery of TGFβ results in reduced local and systemic levels of the active form of TGFβ.This finding suggests potential clinical implications for use of encapsulated TGFβ in the context of IBD and/or pathological TGFβ signaling.

    MATERIALS AND METHODS

    Preparation and characterization of TGFβ and ATRA loaded formulations

    Microsphere preparation: For tissue studies, TGFβ (Peprotech, Rocky Hill, NJ, United States) was encapsulated into bench-top scale, poly-lactic acid (PLA) particles (0.285 mg TGFβ per gram of final drug product; for simplicity and clarity the abbreviation TGFβ refers specifically to TGFβ1, unless otherwise noted) using PIN as described previously[30].ATRA (Sigma) was encapsulated into poly-lactic-co-glycolic acid(PLGA) particles (1 mg of ATRA per gram of particles) using a modification of the solvent evaporation technique as in previous studies[31].

    For PK studies, TGFβ and ATRA loaded microspheres (denoted TPX6001 and TPX7001, respectively) were synthesized at Lonza-Bend, Bend Oregon using a proprietary two-step spray dry process to manufacture larger, scaled up quantities.Briefly, in Step 1, lyophilized protein is mixed with excipients and dispersed.In Step 2,micronized protein + excipients are encapsulated, precipitated and collected.To reduce dose mass, TGFβ and ATRA spray dry drug products were loaded at 1 mg/g and 2 mg/g w/v.The release kinetics, bioactivity, morphology, long-term (1 year)stability, as well as the physicochemical properties of glass transition temperature and crystallinity were essentially identical in the bench lots and spray dried particles (data not shown).

    TGFβ and ATRA loaded PLA and PLGA particles were mixed cage-side in the indicated proportions to create TreXTAM, a proprietary combinatorial product designed to provide both TGFβ and ATRA signals thought to drive the development of regulatory T cells[32-35].

    In vitro drug substance release:Formulations were release-tested using anin vitrorelease assay described previously[24].Briefly, for TGFβ, 0.2 mL of a 10 mg/mL particle suspension was transferred to the wells of a 96-well plate in triplicate.The plate was incubated at 37oC in 5% CO2, the supernatants were sampled at the indicated time points and stored at -20oC until use.ATRA was extracted and measured by HPLC as in our previous studies[36].The immune-reactive, active form of TGFβ was measured by assaying non-acidified samples in an ELISA (R&D Systems Quantikine ELISA kit Catalog# MB100B).This assay does not have significant cross-reactivity or interference with TGFβ2 or TGFβ3, and does not detect the latent form of TGFβ1 without acid treatment.ATRA extraction and analysis was performed as follows: 10 ± 0.1 mg ATRA containing microspheres were weighed into 15 mL Falcon tubes for each terminal time-point.1 mL of 1 × PBS was added and placed on end-over-end rotator at 37 oC.At predetermined time-points, the tubes were centrifuged and supernatant discarded.The remaining microspheres were flash frozen and lyophilized for 24 h.Microsphere samples were then extracted by adding 5 mL of pH 7 mobile phase (68:24:8 ratio of acetonitrile: 1% glacial acetic acid:ethanol) and bath sonicating for 45 min.Extracted samples were then run on a HPLC using a Waters Symmetry C18 Column (5.0 μm, 3.9 mm × 150 mm) at a flow rate of 1 mL/min using pH 7 mobile phase.Absorbance was measured at 356 nm.

    Pharmacokinetic studies

    Animals: The in-life phase of these studies was performed at Comparative Biosciences,Sunnyvale, California.7 to 9-wk old Sprague-Dawley rats (males and females) were kept under standard laboratory conditions with free access to food and water.They were allowed to adapt one week before starting the study.The care and use of laboratory animals was in accordance with relevant IACUC-approved animal use protocols.

    Administration of encapsulated drug products:A 0.5-mL aliquot of TreXTAM (or TPX6001 alone) in aqueous suspension was prepared by reconstitution of drug products (TPX7001 and/or TPX6001) with distilled water and mixed in appropriate w/v proportions to achieve the targeted dosing.Animals were dosed by oral gavage.Blood samples were collected at fixed times after dosing.

    Tissues analysis:7 to 9-wk old male Sprague-Dawley ratsn= 3 per group) were untreated, or treated (oral gavage) with TreXTAM three times per week for four weeks.Four hours after the final dose, gut tissues were taken, frozen at -20oC and stored until used.Tissues were then thawed and homogenized using a glass tube with the pestle insert, in the presence of EDTA-free SIGMAFAST? Protease Inhibitor Cocktail Tablets (Sigma-Aldrich) used as per manufacturer’s instructions.Levels of TGFβ1 and ATRA in lysates were measured as described above.

    Serum analysis:Serum levels of TGFβ1 were measured using an ELISA kit (R&D Systems, Minneapolis, MN; see above) with a slight modification from manufacturer’s instructions.Samples were not acid- activated, minimizing detection of endogenous latent cytokine.For ATRA, a high-performance liquid chromatograph combined with a triple quadrupole mass spectrometer was used as in our previous studies[36].

    SCID mouse CD4+CD25- T cell transfer colitis model

    The model was chosen because it recapitulates a regulatory T cell immunological basis of colitis, and was performed as in our previous studies[1].Briefly:

    Animals:Six to 8-wk old BALB/c and CB-17 SCID mice (males and females; Jackson Laboratories, Bar Harbor, MA, United States) were kept under standard laboratory conditions with free access to food and water and allowed to adapt one week before starting the study.The care and use of laboratory animals was in accordance with a University at Buffalo IACUC-approved animal use protocol.

    Isolation of CD4+CD25- T cells:CD4+ CD25- T-cells were purified from the spleens of na?ve BALB/c mice by magnetic bead separation using MACS?column and separator according to manufacturer’s instructions (Miltenyi Biotech, San Diego, CA,United States).Purity and viability (> 95%) were assessed by flow cytometry(FACScan, Becton Dickinson, San Jose, CA, United States).

    Induction of colitis:Purified CD4+CD25- T-cells were adoptively-transferred to SCID recipients (4 × 105cells per mouse, i.p.).Mice were randomized into groups when 10%of mice show 5% or greater weight loss and/or soft or bloody stools and treatment (3 ×per weekviaoral gavage) started.Daily disease score was recorded for each animal as in our previous studies[1]and summarized for each group as cumulative disease score during treatment.Last recorded values of animals that died during treatment were brought forward.At the end of the treatment period, all mice were sacrificed, and colons scored grossly for pathology on a 0 (normal) to 5 (diseased; elongated,inflamed, lacking definable stools) scale.Histology was also performed as in our previous studies[1].Six to eight H&E sections of colon representing ascending,transverse and descending colon per mouse were evaluated independently, in blinded fashion, by a board-certified pathologist (Pacific Tox Path, LLC, Ellensburg, WA,United States).A composite inflammation score was calculated based on (0-3) severity and extent of cellular infiltration, amount of mucus and degree of proliferation(maximum score of 12).

    Statistical analysis

    Significance (P≤ 0.05) between experimental and control groups was determined using Student’st-test analysis.In experiments with multiple groups, homogeneity of inter-group variance was analyzed by ANOVA.

    RESULTS

    In vitro release patterns of TGFβ and ATRA and typical appearance of PLA and PLGA microsphere particles

    For tissue studies, and for ACT studies, TGFβ and ATRA were encapsulated using PIN or solvent evaporation techniques bench top-processes (respectively) at 0.285 mg/g and 1 mg/g w/w, respectively.At 24 h, both TGFβ and ATRA drug products released bioactive (confirmed using TGFβ sensitive mouse lymphoblast cell line HT-2 or ATRA sensitive murine melanoma B16-F1cells; data not shown) TGFβ or ATRA (Figure 1A and B respectively) as expected, indicating that both drug substances could potentially be delivered in active forms, simultaneously,in vivoafter oral administration.

    TGFβ and ATRA in small and large intestine and MLN after oral Administration of TreXTAM to male rats

    To assess delivery of ATRA and TGFβ to gut, male Sprague-Dawley rats were fed with either blank particles or with TreXTAM (60 mg/kg and 30 mg/kg of TGFβ and ATRA loaded particles; denoted TPX6001 and TPX7001, respectively, and loaded at 0.286 mg/g and 1 mg/g, approximately 17 and 30 μg/kg respectively) three times per week for four weeks.Four hours after the final treatment, small intestine, large intestine and MLN were collected from each animal and frozen at -20oC.ATRA and TGFβ levels in small and large intestine, as well as MLN, were determined by HPLC or ELISA,respectively (limit of detection 0.75 ng/mL and 0.4 pg/TGFβ/100 μg of protein,respectively).Levels of ATRA in small intestine and MLN of treated and untreated animals were at the limit of detection.Levels of ATRA in colon were virtually the same in treated and untreated animals (data not shown).TGFβ was also negligible in small intestine and MLN of treated and untreated animals.However, TGFβ levels in colon of treated animals were decreased over 50% compared to untreated animals (Figure 2).This difference was significant (P= 0.025) suggesting a treatment associated attenuation of endogenous active TGFβ in colon tissue.Since those initial studies, we scaled up production of PLA encapsulated TGFβ (TPX6001) using the proprietary twostep stray dried manufacturing process described in the methods section.Production of PLGA encapsulated ATRA (TPX7001) has also been scaled up using spray drying methods.Release rates and physiochemical properties of the spray dried and bench top materials were virtually identical (data not shown).All pharmacokinetic work to follow was performed using spray-dried TGFβ PLA and ATRA PLGA (loaded at 0.1 and 0.2%, respectively) material.

    Pharmacokinetics following oral administration of TreXTAM

    We could not directly demonstrate simultaneous delivery of TGFβ or ATRA to gut tissue by oral TreXTAM (although we could see biological effects[1]).To further investigate this issuein vivo, and as part of our development efforts, we tested oral TreXTAM in a 28-d GLP rat toxicology study.The relevant pharmacokinetic for ATRA after TreXTAM administration has been published previously[36].Those studies reported that after a single oral TreXAM administration, serum ATRA levels peaked with a Tmaxof 60 min and t ? of 143 min.

    We report here that after oral administration of TreXTAM (30 mg/kg spray-dried encapsulated TGFβ and 30 mg/kg PLGA encapsulated ATRA) three times a week for 25 d, serum TGFβ levels were significantly reduced compared to those observed in the same animals on day 0, prior to any TreXTAM dosing (Figure 3; NB: The level of ELISA detection is approximately 150 pg/mL).This finding was reminiscent of our observations of reduced TGFβ in colon after dosing (Figure 2).We also note that in the pre- dose, na?ve animalsn= 24 per sex) females had higher endogenous levels of TGFβ compared to males (492 ± 107 pg/mLvs324 ± 14 pg/mL).This difference was highly significant (P< 0.0001).Similar observations were reported previously by Knabbeet al[37].

    Oral treatments with PLA encapsulated TGFβ reduce serum levels of TGFβ

    We also tested spray-dried PLA encapsulated TGFβ (TPX6001; loaded at 1 mg/g w/w)given alone in a similar 28-d GLP rat toxicology study (Figure 4).Once again, when similar analyses were performed on naive animals and on the same animals that had been dosed three times per week for 25 d, a dramatic and highly significant (P< 0.01)treatment-related reduction in serum TGFβ levels was evident for all dose groups(Figure 4).Indeed, the reduction in baseline serum TGFβ was dose dependent, in that the difference between the low and high dose group was also significant (P< 0.03).It was also interesting to once again note that in na?ve pre-dose animalsn= 24 per sex),females had significantly (P= 0.001) higher levels of TGFβ than males, (492 ± 107 pg/mLvs324 ± 14 pg/mL) indicating the same gender bias.

    Figure 1 Release profiles of transforming growth factor -loaded poly-lactic acid microspheres and all trans retinoic acid-loaded polylactic-co-glycolic acid microspheres.Transforming growth factor (TGF) was encapsulated in poly-lactic acid (PLA) microspheres (285 μg of TGF per gram of particles) using Phase Inversion Nano-encapsulation (PIN).All trans retinoic acid (ATRA) was encapsulated into poly-lactic-co-glycolic acid (PLGA) microspheres (1 mg of ATRA per gram of particles) using a modification of the solvent evaporation technique (see methods section).A: TGF-loaded microspheres were release-tested using the in vitro release assay as described in the methods section; B: ATRA-loaded microspheres were release-tested using an in vitro extraction assay as described in the methods section.Data are expressed as pg/mL or as μg/mL ± SE.TGFβ: Transforming growth factor ; ATRA: All trans retinoic acid.

    Figure 2 Effect of oral treatment with TreXTAM on levels of transforming growth factor in colon.Treated rats (n =3) received TreXTAM [60 mg/kg encapsulated transforming growth factor (TGF) and 30 mg/kg encapsulated all trans retinoic acid (ATRA)] three times a week for four weeks.Colons of these animals were taken 4 h after the final dose, along with tissues from age and sex matched untreated animals.All tissues were frozen at -20 oC and stored until used.Tissues were then thawed and homogenized using a glass tube with the pestle insert, in the presence of EDTA-free SIGMAFAST? Protease Inhibitor Cocktail Tablets (used as per manufacturer’s instructions).Levels of TGF in lysates were determined by ELISA according to manufacturer’s instructions but without acid activation.(Quantikine, R&D Systems, Minneapolis, MN, United States).Total protein concentration was determined by BCA Protein Assay- Pierce (Thermo Fisher Cat# 23227) Data are expressed as pg/100 μg protein ± standard deviation.TGFβ: Transforming growth factor .

    Effect of TPX6001 on disease in the SCID mouse CD4+CD25- ACT model of IBD

    Figure 3 Baseline serum levels of transforming growth factor in na?ve and TreXTAM treated animals.Blood was taken from na?ve male and female Sprague-Dawley rats (males and females, 3 per sex) before and after treatment with TreXTAM [30 mg/kg encapsulated transforming growth factor (TGF) and 30 mg/kg encapsulated all trans retinoic acid (ATRA)].Animals were dosed by gavage 3 × per week for 25 d.Serum levels of TGFβ were determined by ELISA without acid activation (R&D Systems Quantikine ELISA Catalog# MB100B).TGFβ: Transforming growth factor .

    Figure 4 Baseline serum levels of transforming growth factor in na?ve rats and in poly-lactic acid encapsulated transforming growth factor treated rats.Blood was taken from na?ve Sprague-Dawley rats (males and females, 6 per sex) before and after treatment with poly-lactic acid encapsulated transforming growth factor (TGF).Animals were treated by gavage at doses of 5, 15 or 30 mg/kg, 3 × per week for 25 d.Serum levels of TGFβ were determined by ELISA without acid activation (R&D Systems Quantikine ELISA Catalog# MB100B).Statistical significance (P ≤ 0.02) vs day 25 at 5 mg/kg vs day 25 at 30 mg/kg.All differences between day 0 pre-dose and day 25 pre-dose were significant (P ≤ 0.01).TGFβ: Transforming growth factor .

    We next tested the IBD therapeutic potential of TPX6001 oral treatments when given alone, without ATRA, in the SCID mouse ACT model of IBD.This single, preliminary study used a highly challenging therapeutic iteration of the model.Treatments began at disease onset.There were no significant differences between groups in terms of body weight or disease score at the start of treatment.We found that TPX6001 treatment resulted in significant attenuation of weight loss (Figure 5).The differences between the 5 mg and 40 mg doses (days 3 to 12) were significant (P= 0.01) compared to animals treated with blank microspheres.The difference between the 10 mg and blank groups during that same period achieved only a trend (P= 0.12), possibly because of two deaths in the 10 mg group.It is also interesting to note that the high dose group showed the most benefit for the first 7 d of treatment, but then deteriorated rapidly.At the end of the study, for each group, we calculated cumulative disease score during treatment (blank fed group = 52; 5, 10 and 40 mg treatment groups = 49.5,52.6, and 47, respectively); colon weight to length ratios (blank fed group = 55.3 ± 14.3;healthy age and sex matched controls = 27.9 ± 4.4; 5, 10 and 40 mg treatment groups =52.8 ± 9.1, 56.5.± 15.3, and 57.4 ± 9.9, respectively), gross pathology (blank fed group =2.9 ± 0.9; 5, 10 and 40 mg treatment groups = 3.7 ± 1.4, 2.4.± 1.4, and 3.8 ± 1.1,respectively) and histology composite inflammation scores (blank fed group = 8.75,and 5, 10 and 40 mg treatment groups = 9.4, 7.8, and 8.1, respectively).We found no significant differences, except at the 10 mg dose (P= 0.003), which again, may have been biased by the deaths of 2 animals in that group.We also note a trend in favor of treatment with respect to cumulative disease score, in the high dose group (P= 0.08).Therefore, we conclude only slight, transient benefit of TPX6001 treatment in this iteration of the ACT model.

    Figure 5 Therapeutic activity of transforming growth factor β loaded particles (TPX6001) in the SCID mouse adoptive CD4+ CD25- T-cell transfer model of inflammatory bowel disease.Mice (n = 6-9 per group) with established disease were weighed (day 0) and fed transforming growth factor β1 microspheres (5, 10, or 40 mg/mouse), or blank microspheres (40 mg/mouse) in 0.2 ml water 3 times per week for 2 wk.Mice were monitored for overall disease score and weighed 3 times per week for two weeks.Mice were sacrificed 2 d after the last dose, serum taken, colons weighed and measured; and colons samples prepared for histological analysis (five randomly selected sections from each mouse).Data are expressed as % change in body weight relative to day of first treatment.5 and 40 mg/mouse TPX6001-treated groups were significantly different (P = 0.01 on days 3-12) from animals treated with blank microspheres.

    Multiple (28 d) oral treatments (thrice weekly) with either TreXTAM or encapsulated TGFβ were safe and well tolerated at the highest doses tested

    For both TreXTAM and PLA encapsulated TGFβ GLP pharmacokinetic studies, full industry standard toxicology analyses, including clinical observations clinical pathology, necropsy, histopathology and ophthalmology, were also performed on both male and female animals.There were no statistically significant differences in body weights or weekly food intake among groups, and no significant organ weight changes.There were no test article-related histopathological or other findings and no fibrosis was observed with even the highest doses at the end of treatment (Day 28) or at the end of a 56-d recovery period (data not shown).Encapsulated TGFβ, when given alone was as safe and as well tolerated as the TreXTAM combination.

    DISCUSSION

    We report here that oral TreXTAM produced a surprising and dramatic decrease in serum and colonic TGFβ levels.While we could not directly demonstrate simultaneous delivery of both drug substances to gut tissues, ourin vitroand pharmacodynamics observations suggest that it was achieved.In animals given either TreXTAM or PLA encapsulated TGFβ (TPX6001) alone 3 times per week for 25 d, we observed dramatically lower serum TGFβ compared to the same animals before dosing.We also found evidence for a transient benefit of oral TPX6001, at least in terms of weight loss attenuation, in the murine adoptive cell transfer (ACT) model of IBD.

    TreXTAM is being developed as treatment for Crohn’s disease (CD) and ulcerative colitis (UC).CD and UC are chronic disorders of the GI tract causing significant morbidity for over 1.4 million Americans[38].An appreciation of common inflammatory pathways led to the joint designation “IBD”.Symptoms include diarrhea, nausea,abdominal pain, weight loss, increased risk for colorectal cancer[39]and can be fatal[40].Although etiologies are incompletely understood, genetic, immunologic and environmental factors all make significant contributions[38,41].Human and animal studies implicate abnormal responses to commensal microflora and perturbed local immune homeostasis[38,39,41].‘Biologics’, macromolecules that target inflammatory lymphocytes or the cytokines they produce[42]have emerged as a new class of highly effective treatments.However, an estimated 30% of patients will not respond and of those who initially respond, 50% relapse within a year.A more recent review indicates only modest impact on surgical intervention rates[43].The need for novel, targeted therapies remains acute.TreXTAM aims to address that need by taking advantage of the synergistic effects of ATRA and TGFβ on the differentiation and stabilization of regulatory T cells[2].

    TGFβ is a pleiotropic cytokine with multiple effects on many cell types.It is a key regulator of T-cell biology, impacting thymocyte development, differentiation and effector function[44].On the one hand, complete loss of TGFβ signaling leads to lymphoproliferative autoimmunity[45-47], on the other hand, systemic administration in microgram doses protects in several autoimmune disease models[48-51].Unfortunately,TGFβ is also associated with serious side effects, including pulmonary fibrosis[52-55],scleroderma[56], chronic GVHD[57]and glomerulonephropathies[58].To circumvent these toxicities, local deliveryviagene therapy has been proposed, but is inconvenient,transitory, imprecise and immunogenic[48,50,59].There is no means to control signal transcription or translation, dose schedule, release rates or unwanted immune responses.TreXTAM, aims to circumvent this problems by local delivery and reduces systemic exposure of drug substances with the hope of reducing effective doses and toxicities.

    Because of the known fibrotic effects of TGFβ, exacerbation of fibrosis in the context of IBD was a serious concern of oral TreXTAM treatment.The results reported here suggest the opposite might be true, especially in colon, where TreXTAM reduced endogenous TGFβ levels.28-d TreXTAM repeat dosing studies in rats, like the one reported here for encapsulated TGFβ alone, showed no TreXTAM induced fibrosis in any organ including small intestines and colon (data not shown).Further, we tested TreXTAM, both in healthy mice and in SCID animals with CD4+ CD25- induced colitis, for up to 8 wk, and likewise, found no increases in fibrosis in any organ (Auciet al, unpublished observations).Considering the results reported here, oral treatment with TreXTAM, or even treatment with encapsulated TGFβ alone, may be useful to stimulate autocrine negative feedback and reduce TGFβ levels, to prevent IBD associated fibrosis.

    Our inability to detect increased TGFβ in small intestine and MLN after TreXTAM treatment may be due to insignificant amounts of TGFβ delivered despite effective particle uptake in the Peyer’s patches and MLN(7).This may relate to the failure of the particles to reach the colon or rapid degradation and/or deactivation of the released TGFβ.Uptake by other tissues, binding to cell surface proteins or other factors, as well as the potential conversion of TGFβ1 to TGFβ2, 3 or its latent form, would have prevented an increase from being detected.Perhaps most surprisingly, we observed a highly significant TreXTAM-associated decrease (approximately 50%) of active TGFβ in the colon.While this may relate to effects of the particles themselves, a more intriguing possibility involves ATRA amelioration of TGFβ expression and signaling[60].Several studies report ATRA decreases TGFβ levels and/or signaling in various tissues[61-64].ATRA modification of TGFβ signaling may also help explain the lack of treatment associated fibrosis observed in our previous studies[1].Reduction of endogenous TGFβ in colon and its simultaneous delivery to immune structures such as Peyer’s patches and MLN may contribute to the TreXTAM-associated benefits in models of IBD.Like observations in colon, decreases in systemic TGFβ were observed when the encapsulated cytokine was delivered with ATRA in the form of TreXTAM,but also when given alone.Therefore, at least the systemic attenuation of TGFβ levels do not require ATRA and can be achieved with just the encapsulated cytokine.The role of TreXTAM in IBD, including its prophylactic and/or therapeutic usefulness for Crohn’s disease and/or colitis, awaits further studies in various models aimed at determining the contribution each component plays in the efficacy observed.

    Our finding of higher levels of TGFβ in femalevsmale rats is reminiscent of other studies in humans[65]and in non-human primates, where TGFβ levels were found to be higher in young females as compared to males.Interestingly, TGFβ levels decreased with age in females, and increased with age in males, suggesting effect of sex hormones[66].The wide literature describing activities of TGFβ in the context of autoimmunity and infection has already been extensively reviewed[67], and its consideration is beyond the scope of this work.Suffice to say that an important intersection for the cross talk between TGFβ signaling pathways and sex hormones may lie at the generation and stabilization of regulatory T cells.

    Reminiscent of our observations with TreXTAM in tissue, we found that oral TPX6001 when given alone, without ATRA, also reduced serum levels of the endogenous cytokine.The mechanism(s) by which oral treatment with encapsulated TGFβ could lead to reduction in systemic and tissue levels remain unknown.They may relate to synthesis or release of mediators by cells, increased uptake and/or deactivation by other tissues[68]and/or effects on pathways specific to immune structures of the gut.TGFβ is synthesized as an inactive precursor, a complex consisting of a TGFβ dimer, the latency-associated protein, and latent TGFβ binding protein[69].Before TGFβ can exert its biological effects, both must be dissociated.Therefore, our findings may also relate to specific activation/deactivation pathways,which may be controlled by the gut.It is also possible that our findings relate to switching between immunologically (ELISA) distinct isoforms of TGFβ (1, 2 or 3)[70].The potential biological significance of such switching is unclear.

    To our knowledge, we were the first to administer PLA encapsulated TGFβviathe oral route[1].Our preliminary observations in the ACT model of IBD suggest only a transient benefit of oral TPX6001 treatment.However, several studies report activities of oral TGFβ, when given as an intact protein.Shiouet al[71]reported that oral administration of TGFβ (30 ng/mL) suppressed pro inflammatory cytokine production (including IL-6 and IL-8) in the gut of rat pups.The suppression was associated with suppressed NF-κB signaling.Systemic TGFβ levels were not measured.An earlier publication by Andoet al[72]reported increased serum TGFβ in mice after oral administration of the intact protein.Those studies also reported enhancement of oral tolerance.Additional studies in the ACT model, as well as other models of acute and chronic IBD, will be necessary to fairly evaluate the therapeutic potential of oral TPX6001 when given alone in IBD and perhaps also in other specific clinical situations where increasing TGFβ levels are pathogenic, for example against certain challenging forms of breast cancer[73].Such studies are subjects of forthcoming work from our laboratories.

    CONCLUSION

    These observations suggest a negative feedback mechanism in the gut whereby local delivery of TGFβ results in reduced local and systemic levels of the active form of TGFβ.Our findings suggest potential clinical implications for use of encapsulated TGFβ, perhaps in the context of IBD and/or other instances of fibrosis and/or pathological TGFβ signaling.

    ARTICLE HIGHLIGHTS

    Research background

    TreXTAM?is a combination of transforming growth factor beta (TGFβ) and all trans retinoic acid (ATRA) microencapsulated for oral delivery to immune structures of the gut.It is in development as a novel treatment for inflammatory bowel disease (IBD).

    Research motivation

    When given together, ATRA and TGFβ signals synergize in promoting the differentiation and stabilization of regulatory T cells.

    Research objectives

    This is a completely novel strategy for the treatment of IBD, as no similar products currently exist.TreXTAM would represent an entirely novel IBD treatment modality.

    Research methods

    During TreXTAM development, we studied TGFβ pharmacokinetics after oral administration of TreXTAM, or after the encapsulated cytokine (TPX6001) was given alone, without ATRA.This is required for combinatorial products.

    Research results

    We made the surprising discovery that oral administration of TreXTAM dramatically reduced TGFβ levels in colon and in blood, to below baseline levels.When encapsulated TGFβ (TPX6001) was given alone, three times a week for 25 d, we likewise observed serum TGFβ decreases below baseline (untreated) levels.Oral treatment with TPX6001 alone transiently ameliorated weight loss in the murine adoptive cell transfer model of IBD, chosen because it recapitulates regulatory T cell immunology associated with disease.

    Research conclusions

    These observations suggest a negative feedback mechanism in the gut whereby local delivery of TGFβ results in reduced local and systemic levels of the active form of TGFβ.This finding suggests potential clinical implications for use of encapsulated TGFβ in the context of IBD and/or pathological TGFβ signaling.

    Research perspectives

    Additional studies in the ACT model, as well as other models of acute and chronic IBD, will be necessary to fairly evaluate the therapeutic potential of oral TreXTAM, as well as TPX6001 when given alone in IBD, autoimmune diseases, and perhaps also in other specific clinical situations where increasing TGFβ levels are pathogenic, for example against certain challenging forms of breast cancer.Such studies are subjects of forthcoming work from our laboratories.

    av国产久精品久网站免费入址| av免费观看日本| 乱码一卡2卡4卡精品| 久久精品久久精品一区二区三区| 国产精品成人在线| 一个人免费看片子| 亚洲国产最新在线播放| 少妇丰满av| 在线天堂最新版资源| 国产 一区 欧美 日韩| 99久久精品国产国产毛片| 黑人高潮一二区| 制服丝袜香蕉在线| 午夜视频国产福利| 妹子高潮喷水视频| 久久午夜福利片| 中文精品一卡2卡3卡4更新| 免费观看在线日韩| 成人综合一区亚洲| 久久精品夜色国产| 国产精品精品国产色婷婷| 99热国产这里只有精品6| 99视频精品全部免费 在线| 国产高清三级在线| 国产成人aa在线观看| 一级二级三级毛片免费看| av播播在线观看一区| 亚洲国产成人一精品久久久| 亚洲国产欧美在线一区| av福利片在线观看| 欧美一级a爱片免费观看看| 亚洲欧美一区二区三区国产| 在线观看美女被高潮喷水网站| 九九久久精品国产亚洲av麻豆| 男女啪啪激烈高潮av片| 性高湖久久久久久久久免费观看| 99久久精品一区二区三区| 欧美成人午夜免费资源| 简卡轻食公司| 免费观看无遮挡的男女| 成人影院久久| 婷婷色麻豆天堂久久| 99视频精品全部免费 在线| 午夜免费男女啪啪视频观看| 精品人妻一区二区三区麻豆| 欧美 日韩 精品 国产| 国精品久久久久久国模美| 日本vs欧美在线观看视频 | 国产色爽女视频免费观看| 纯流量卡能插随身wifi吗| 下体分泌物呈黄色| 日本欧美国产在线视频| 日韩成人av中文字幕在线观看| 丰满人妻一区二区三区视频av| 亚洲熟女精品中文字幕| 国产熟女欧美一区二区| 色5月婷婷丁香| 高清在线视频一区二区三区| 亚洲av综合色区一区| 免费黄色在线免费观看| 日本一二三区视频观看| 亚洲va在线va天堂va国产| 最近中文字幕高清免费大全6| 亚洲成人手机| 高清欧美精品videossex| 亚洲精品成人av观看孕妇| 妹子高潮喷水视频| 狠狠精品人妻久久久久久综合| 中文在线观看免费www的网站| 国产 一区 欧美 日韩| 日韩视频在线欧美| 熟女av电影| 日韩,欧美,国产一区二区三区| .国产精品久久| 国产欧美亚洲国产| 日本-黄色视频高清免费观看| 久久热精品热| 精品久久久久久久久亚洲| 久久99热这里只有精品18| 国产一区亚洲一区在线观看| 国产男女内射视频| 久久久精品94久久精品| 成人漫画全彩无遮挡| 中国国产av一级| 搡老乐熟女国产| 欧美另类一区| 综合色丁香网| 亚洲高清免费不卡视频| 久久久久国产精品人妻一区二区| 欧美丝袜亚洲另类| 韩国av在线不卡| 亚洲欧美中文字幕日韩二区| 免费看av在线观看网站| 国产欧美日韩一区二区三区在线 | 久久久久精品久久久久真实原创| 久久久久视频综合| 激情五月婷婷亚洲| 丰满迷人的少妇在线观看| 91久久精品国产一区二区三区| 日本av手机在线免费观看| 国产精品熟女久久久久浪| 在线 av 中文字幕| 婷婷色av中文字幕| 亚洲不卡免费看| 精品亚洲乱码少妇综合久久| 成人午夜精彩视频在线观看| 久久av网站| 制服丝袜香蕉在线| 91久久精品电影网| 少妇被粗大猛烈的视频| www.色视频.com| 亚州av有码| 丰满乱子伦码专区| 久久久久人妻精品一区果冻| 日日摸夜夜添夜夜爱| 高清不卡的av网站| 久久国内精品自在自线图片| 三级国产精品片| 内地一区二区视频在线| 精品亚洲成国产av| 麻豆成人av视频| 女人久久www免费人成看片| 亚洲在久久综合| 亚洲在久久综合| 伊人久久精品亚洲午夜| 五月开心婷婷网| 午夜福利网站1000一区二区三区| 91aial.com中文字幕在线观看| 国产精品av视频在线免费观看| 日韩中文字幕视频在线看片 | 直男gayav资源| 亚洲丝袜综合中文字幕| 国产伦在线观看视频一区| 在线天堂最新版资源| 2022亚洲国产成人精品| 国内揄拍国产精品人妻在线| 丰满乱子伦码专区| 激情五月婷婷亚洲| 国产亚洲午夜精品一区二区久久| 大码成人一级视频| 国产欧美另类精品又又久久亚洲欧美| 一区二区av电影网| 亚洲av.av天堂| 一本色道久久久久久精品综合| 欧美精品国产亚洲| 七月丁香在线播放| www.色视频.com| 国产成人精品一,二区| 亚洲精品国产av蜜桃| 久久久久久久国产电影| 欧美成人午夜免费资源| 亚洲精品一区蜜桃| 一级爰片在线观看| av在线app专区| 亚洲av成人精品一区久久| 蜜桃在线观看..| 久久精品国产亚洲av涩爱| 内射极品少妇av片p| 久久精品国产亚洲av涩爱| 久久久久久久久久成人| 伦精品一区二区三区| 人人妻人人澡人人爽人人夜夜| 欧美最新免费一区二区三区| 亚洲av欧美aⅴ国产| 欧美精品一区二区免费开放| 久久精品久久久久久噜噜老黄| 亚洲综合色惰| 高清av免费在线| 综合色丁香网| 最后的刺客免费高清国语| 免费观看的影片在线观看| 亚洲人与动物交配视频| 欧美成人精品欧美一级黄| 亚洲成人一二三区av| 免费看av在线观看网站| 纯流量卡能插随身wifi吗| 久久久久久久大尺度免费视频| 麻豆乱淫一区二区| 色视频www国产| 国产v大片淫在线免费观看| 在线精品无人区一区二区三 | 久久 成人 亚洲| 亚洲成人手机| 欧美xxxx黑人xx丫x性爽| 亚洲成人手机| 国产成人免费无遮挡视频| 观看美女的网站| 国产精品爽爽va在线观看网站| 多毛熟女@视频| 国产男女内射视频| 精品午夜福利在线看| 啦啦啦在线观看免费高清www| av又黄又爽大尺度在线免费看| 九九久久精品国产亚洲av麻豆| 国内揄拍国产精品人妻在线| 日韩不卡一区二区三区视频在线| 日本午夜av视频| 3wmmmm亚洲av在线观看| 亚洲欧美成人综合另类久久久| 一区二区av电影网| 99久久中文字幕三级久久日本| 日日撸夜夜添| av又黄又爽大尺度在线免费看| 精品久久久久久久久av| av一本久久久久| 日韩大片免费观看网站| 国产亚洲91精品色在线| 亚洲av福利一区| 日韩av免费高清视频| 男女边吃奶边做爰视频| 激情五月婷婷亚洲| 久久影院123| 免费观看性生交大片5| av卡一久久| 美女福利国产在线 | 国产片特级美女逼逼视频| 国产美女午夜福利| 51国产日韩欧美| 久久精品国产亚洲网站| 韩国高清视频一区二区三区| 国产中年淑女户外野战色| 久久人人爽人人片av| 免费看av在线观看网站| 国产精品久久久久久久久免| av在线app专区| 精品一品国产午夜福利视频| 大香蕉久久网| 精品国产一区二区三区久久久樱花 | 有码 亚洲区| 国产精品爽爽va在线观看网站| 搡老乐熟女国产| 欧美日韩视频高清一区二区三区二| 在线观看免费高清a一片| 成人无遮挡网站| 日韩欧美精品免费久久| 男人和女人高潮做爰伦理| 久久久久网色| 久久精品夜色国产| 欧美xxxx性猛交bbbb| 免费黄色在线免费观看| 特大巨黑吊av在线直播| 国产91av在线免费观看| 最近最新中文字幕大全电影3| 国产精品国产av在线观看| 欧美日韩综合久久久久久| 亚洲成色77777| 看十八女毛片水多多多| 99久久人妻综合| 九九爱精品视频在线观看| 国产日韩欧美在线精品| 亚洲精品一二三| 亚洲人成网站高清观看| 久久久久久久亚洲中文字幕| 欧美一级a爱片免费观看看| 成年女人在线观看亚洲视频| 久久久欧美国产精品| 亚洲国产日韩一区二区| 国产在线视频一区二区| 国产av码专区亚洲av| 亚洲国产高清在线一区二区三| 亚洲欧美一区二区三区黑人 | 国产一区亚洲一区在线观看| 97在线视频观看| 高清不卡的av网站| 午夜福利影视在线免费观看| 下体分泌物呈黄色| 久久精品久久久久久久性| 久久精品国产a三级三级三级| 免费看光身美女| 五月伊人婷婷丁香| 舔av片在线| 久久久色成人| 99热这里只有精品一区| 在线精品无人区一区二区三 | 亚洲婷婷狠狠爱综合网| 国产精品蜜桃在线观看| 麻豆成人av视频| 亚洲天堂av无毛| 黄色怎么调成土黄色| 久久99热6这里只有精品| 中文资源天堂在线| 亚洲精品久久久久久婷婷小说| 激情五月婷婷亚洲| 色视频www国产| 国产在线视频一区二区| 黑人高潮一二区| 久久99热6这里只有精品| 免费看光身美女| 99久久中文字幕三级久久日本| 韩国av在线不卡| 网址你懂的国产日韩在线| 日韩不卡一区二区三区视频在线| 亚洲婷婷狠狠爱综合网| 精品亚洲乱码少妇综合久久| 一级毛片黄色毛片免费观看视频| 中国三级夫妇交换| 热99国产精品久久久久久7| h视频一区二区三区| 亚洲av国产av综合av卡| a级毛片免费高清观看在线播放| 国产片特级美女逼逼视频| 成年女人在线观看亚洲视频| 国产免费福利视频在线观看| 男女免费视频国产| 日本wwww免费看| 六月丁香七月| 亚洲人成网站在线播| 免费大片黄手机在线观看| 国产午夜精品久久久久久一区二区三区| 国产国拍精品亚洲av在线观看| 亚洲精品国产av成人精品| 香蕉精品网在线| 不卡视频在线观看欧美| 亚洲美女黄色视频免费看| 中国国产av一级| 少妇熟女欧美另类| 国产又色又爽无遮挡免| 久久久午夜欧美精品| 欧美国产精品一级二级三级 | 丰满乱子伦码专区| 人妻少妇偷人精品九色| 国产免费又黄又爽又色| 亚洲欧美精品自产自拍| 亚洲自偷自拍三级| 热99国产精品久久久久久7| 少妇精品久久久久久久| 日本免费在线观看一区| 亚洲色图综合在线观看| 亚洲av综合色区一区| 精品少妇黑人巨大在线播放| 少妇人妻一区二区三区视频| 大香蕉97超碰在线| 高清视频免费观看一区二区| 自拍偷自拍亚洲精品老妇| 亚洲欧美日韩卡通动漫| 高清在线视频一区二区三区| 国产女主播在线喷水免费视频网站| 青春草亚洲视频在线观看| 久久久久久久大尺度免费视频| 身体一侧抽搐| 校园人妻丝袜中文字幕| 免费黄网站久久成人精品| 成年美女黄网站色视频大全免费 | 国产欧美日韩精品一区二区| 亚洲精品aⅴ在线观看| 观看av在线不卡| 亚洲婷婷狠狠爱综合网| 丝袜喷水一区| 欧美xxⅹ黑人| 日本与韩国留学比较| 偷拍熟女少妇极品色| 欧美成人a在线观看| 熟女人妻精品中文字幕| 精品一品国产午夜福利视频| 97在线人人人人妻| 久久av网站| 久久精品国产自在天天线| 欧美成人a在线观看| 观看免费一级毛片| 久久久午夜欧美精品| 女人十人毛片免费观看3o分钟| 国产在线一区二区三区精| 亚洲第一区二区三区不卡| 一级片'在线观看视频| 最近的中文字幕免费完整| 久久毛片免费看一区二区三区| 亚洲精品久久久久久婷婷小说| 成人18禁高潮啪啪吃奶动态图 | 国产高清三级在线| 午夜福利高清视频| 99九九线精品视频在线观看视频| 国产亚洲一区二区精品| 精品少妇黑人巨大在线播放| 草草在线视频免费看| 好男人视频免费观看在线| 国产淫语在线视频| 国产高潮美女av| 免费大片18禁| 特大巨黑吊av在线直播| .国产精品久久| 中文精品一卡2卡3卡4更新| 久久人人爽人人片av| 成人免费观看视频高清| 在线观看三级黄色| 免费在线观看成人毛片| 色5月婷婷丁香| 免费播放大片免费观看视频在线观看| 国产精品嫩草影院av在线观看| 91精品一卡2卡3卡4卡| 日韩不卡一区二区三区视频在线| 欧美日韩国产mv在线观看视频 | 国产极品天堂在线| 精品一区在线观看国产| 亚洲欧美日韩另类电影网站 | 精品国产一区二区三区久久久樱花 | 精品国产一区二区三区久久久樱花 | 男女啪啪激烈高潮av片| 狂野欧美激情性xxxx在线观看| 日韩一区二区三区影片| 久久精品国产亚洲av涩爱| 视频区图区小说| 午夜福利影视在线免费观看| 国产色婷婷99| 国产黄色免费在线视频| 久久人人爽av亚洲精品天堂 | 一区在线观看完整版| 欧美成人一区二区免费高清观看| 亚洲人成网站高清观看| 日本黄大片高清| a级毛片免费高清观看在线播放| 国产视频内射| 看免费成人av毛片| 爱豆传媒免费全集在线观看| 国产黄色视频一区二区在线观看| 少妇的逼水好多| 亚洲美女黄色视频免费看| 国产免费视频播放在线视频| av在线老鸭窝| 久久久亚洲精品成人影院| 一区二区三区四区激情视频| 国产精品久久久久久久久免| 亚洲在久久综合| 精品久久久久久久久av| 男人狂女人下面高潮的视频| av福利片在线观看| 国产成人精品婷婷| 欧美xxxx性猛交bbbb| 日本黄色日本黄色录像| 一级毛片 在线播放| 熟女人妻精品中文字幕| 不卡视频在线观看欧美| 久久久久视频综合| 久久精品久久久久久久性| 国产男女超爽视频在线观看| 国产国拍精品亚洲av在线观看| 国产精品一二三区在线看| 亚洲av日韩在线播放| 免费大片18禁| 亚洲精品一区蜜桃| 午夜福利高清视频| 久久精品久久精品一区二区三区| 国产 一区 欧美 日韩| 午夜福利在线在线| 天美传媒精品一区二区| 亚洲国产精品国产精品| 亚洲真实伦在线观看| 国产在视频线精品| av视频免费观看在线观看| 又大又黄又爽视频免费| 热99国产精品久久久久久7| 国产成人一区二区在线| 日日撸夜夜添| 久久久久性生活片| 色综合色国产| 中文精品一卡2卡3卡4更新| 性色av一级| 在线天堂最新版资源| 亚洲国产精品一区三区| av线在线观看网站| 精品人妻偷拍中文字幕| 毛片女人毛片| 女性生殖器流出的白浆| 国产亚洲最大av| 99热这里只有是精品50| 欧美日韩在线观看h| 狂野欧美激情性bbbbbb| 日日摸夜夜添夜夜添av毛片| 日日啪夜夜撸| 舔av片在线| 丝袜喷水一区| av免费观看日本| 亚洲欧美中文字幕日韩二区| 色综合色国产| 一级毛片电影观看| 亚洲图色成人| 精品人妻视频免费看| 国产老妇伦熟女老妇高清| 女性生殖器流出的白浆| 国产精品三级大全| 日日啪夜夜爽| 99re6热这里在线精品视频| 日本vs欧美在线观看视频 | 偷拍熟女少妇极品色| 男女无遮挡免费网站观看| 一区二区av电影网| 久久人人爽人人片av| 国产精品久久久久久久电影| 成人漫画全彩无遮挡| 久久久久久久亚洲中文字幕| 精华霜和精华液先用哪个| 女性被躁到高潮视频| 国产精品.久久久| 伦理电影免费视频| 高清毛片免费看| 国产精品福利在线免费观看| 熟女人妻精品中文字幕| 久久久久久久久久人人人人人人| 一级毛片久久久久久久久女| 免费少妇av软件| 亚洲美女视频黄频| 99热这里只有是精品在线观看| 成人毛片a级毛片在线播放| 啦啦啦视频在线资源免费观看| 人妻 亚洲 视频| 美女国产视频在线观看| 国产精品国产三级国产专区5o| av.在线天堂| 啦啦啦中文免费视频观看日本| 80岁老熟妇乱子伦牲交| 色吧在线观看| 内地一区二区视频在线| 国产真实伦视频高清在线观看| 国产精品熟女久久久久浪| 黄色配什么色好看| 91久久精品国产一区二区三区| 国产 一区 欧美 日韩| 精华霜和精华液先用哪个| 熟女人妻精品中文字幕| 日本免费在线观看一区| 卡戴珊不雅视频在线播放| 日韩在线高清观看一区二区三区| 九九久久精品国产亚洲av麻豆| 啦啦啦啦在线视频资源| 日韩人妻高清精品专区| 午夜福利影视在线免费观看| 伊人久久精品亚洲午夜| 伦理电影免费视频| 欧美一级a爱片免费观看看| 搡女人真爽免费视频火全软件| 久久精品夜色国产| 全区人妻精品视频| 男男h啪啪无遮挡| 91狼人影院| 激情五月婷婷亚洲| 美女中出高潮动态图| 最近最新中文字幕免费大全7| 免费黄网站久久成人精品| av在线观看视频网站免费| 99久国产av精品国产电影| 人人妻人人澡人人爽人人夜夜| 中国国产av一级| 日韩欧美一区视频在线观看 | av在线观看视频网站免费| 麻豆成人午夜福利视频| 欧美日韩综合久久久久久| 校园人妻丝袜中文字幕| 小蜜桃在线观看免费完整版高清| 亚洲av福利一区| 国产大屁股一区二区在线视频| 亚洲美女视频黄频| 国产爽快片一区二区三区| 亚洲美女黄色视频免费看| 国产中年淑女户外野战色| 日韩欧美 国产精品| 亚洲欧美清纯卡通| 成人亚洲欧美一区二区av| 在线观看免费高清a一片| 看十八女毛片水多多多| 国精品久久久久久国模美| 伦精品一区二区三区| 亚洲精品国产色婷婷电影| 免费看不卡的av| 欧美另类一区| 少妇的逼水好多| 2018国产大陆天天弄谢| 国产在线男女| 久久ye,这里只有精品| 另类亚洲欧美激情| 777米奇影视久久| 成人一区二区视频在线观看| 日本vs欧美在线观看视频 | 99久国产av精品国产电影| 人人妻人人澡人人爽人人夜夜| 久久6这里有精品| 麻豆成人av视频| 一级毛片久久久久久久久女| 亚洲国产精品999| 国产精品精品国产色婷婷| kizo精华| 国产视频首页在线观看| 欧美老熟妇乱子伦牲交| 中国国产av一级| 色5月婷婷丁香| 少妇裸体淫交视频免费看高清| 亚洲无线观看免费| 天堂8中文在线网| 亚洲国产日韩一区二区| av国产精品久久久久影院| 久久久久久久久久久免费av| 亚洲成人手机| 国产男女超爽视频在线观看| 欧美日韩国产mv在线观看视频 | 久久人人爽av亚洲精品天堂 | 色哟哟·www| 80岁老熟妇乱子伦牲交| 男女国产视频网站| 蜜桃在线观看..| 一级二级三级毛片免费看| 免费看光身美女| 卡戴珊不雅视频在线播放| 色网站视频免费| 美女cb高潮喷水在线观看| 两个人的视频大全免费| a 毛片基地| 亚洲精品亚洲一区二区| 久久人人爽人人片av| 欧美精品一区二区免费开放| 男人狂女人下面高潮的视频| av国产免费在线观看| 熟妇人妻不卡中文字幕| 久久久成人免费电影| 少妇精品久久久久久久| 一级片'在线观看视频| 国产精品国产av在线观看| 一级毛片久久久久久久久女|